- 7 Doctor-Approved Tips for Outdoor Fitness Without Injury
- How a Baby’s Brain Grows in the First Years of Life
- FDA Approves Once-Monthly Andembry for Hereditary Angioedema
- Trump Administration To End Lifeline for LGBTQ+ Youth This July
- Chicken Alfredo Meals Recalled After Listeria Outbreak Kills 3
- FDA Approves First Twice-a-Year HIV Prevention Shot
- Well-being Might Be Important To Memory
- Fecal Transplant Potential First-Line Treatment For C. Difficile Infection
- New Blood Test Promises Pain-Free Diagnosis Of Celiac Disease
- Parents Are Pouring More Time, Money Into Youth Sports
Antiviral Combination Approved for Hepatitis C

Viekira Pak, a combination of four antiviral drugs — ombitasvir, paritaprevir, ritonavir and dasabuvir — has been approved by the U.S. Food and Drug Administration to treat hepatitis C infection, including a major complication, cirrhosis of the liver.
Some 3.2 million Americans are infected with the viral disease, which can lead to complications including reduced liver function, liver failure or liver cancer, the FDA said in a news release. Most infected people have no symptoms before onset of liver damage.
Without proper treatment, 15 percent to 30 percent will develop advanced liver disease known as cirrhosis, the agency said.
The combination pack’s safety and effectiveness were evaluated in clinical studies involving more than 2,300 people with chronic hepatitis C, with and without cirrhosis. The most common side effects included fatigue, itching, weakness, lack of energy, nausea and trouble sleeping.
Viekira Pak is marketed by AbbVie Inc., based in North Chicago.
More information
Visit the FDA to learn more.
Source: HealthDay
Copyright © 2025 HealthDay. All rights reserved.